enGene Therapeutics Inc

ENGNNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

67.0M

on 2026-07-31, from 44.2M on 2024-04-30 10-Q ↗

a raise that quarter, at its price

Newest

Filed

S-3 of 2026-02-19. Size not read. 1 prospectus supplement filed under it since. S-3 ↗

$100.0M

Leerink Partners, agreement of 2026-03-09. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

8.55M

Warrants of every class as tagged in the XBRL facts on 2026-07-31. 10-Q ↗

Cash

10.3 quarters

$266.3M on 2026-07-31 ÷ $25.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-11-12	Public offering	not read	$8.50	$130.0M	424B5 ↗

Also on file: up to $35.0M term loan agreed 2026-01-20 8-K ↗